Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 16:6:100178.
doi: 10.1016/j.crphar.2024.100178. eCollection 2024.

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients

Simone Parisi  1 , Becciolini Andrea  2 , Ditto Maria Chiara  1 , Alberto Lo Gullo  3 , Larosa Maddalena  4 , Scolieri Palma  5 , Addimanda Olga  6 , Reta Massimo  6 , Marino Paroli  7 , Caccavale Rosalba  7 , Visalli Elisa  8 , Foti Rosario  8 , Amato Giorgio  8 , De Lucia Francesco  8 , Dal Bosco Ylenia  8 , Foti Roberta  8 , Farina Antonella  9 , Girelli Francesco  10 , Bernardi Simone  10 , Camellino Dario  4 , Bianchi Gerolamo  4 , Colina Matteo  11   12 , Andracco Romina  13 , Mansueto Natalia  13 , Ferrero Giulio  13 , Del Medico Patrizia  14 , Molica Colella Aldo  15 , Franchina Veronica  16 , Molica Colella Francesco  17 , Lumetti Federica  18 , Sandri Gilda  19 , Salvarani Carlo  19 , Priora Marta  20 , Ianniello Aurora  21 , Nucera Valeria  21 , Santilli Daniele  2 , Lucchini Gianluca  2 , Giuditta Adorni  2 , Di Donato Eleonora  2 , Bravi Elena  22 , Platè Ilaria  22 , Arrigoni Eugenio  22 , Bezzi Alessandra  23 , Focherini Maria Cristina  23 , Mascella Fabio  23 , Bruzzese Vincenzo  5 , Ravagnani Viviana  24 , Fiorenza Alessia  25 , Rovera Guido  25 , Vitetta Rosetta  25 , Marchetta Antonio  26 , Volpe Alessandro  26 , Ometto Francesca  27 , Ariani Alarico  2 , Fusaro Enrico  1
Affiliations

Analysis of survival rate and persistence predictors of baricitinib in real-world data from a large cohort of rheumatoid arthritis patients

Simone Parisi et al. Curr Res Pharmacol Drug Discov. .

Abstract

Objectives: The persistence in therapy of rheumatoid arthritis drugs and particularly bDMARD is a limiting factor for their long-term use. The randomized controlled trials (RCTs) may not reflect real-world contexts due to strict inclusion and exclusion criteria. Baricitinib, which targets both JAK1 and JAK2, has been used in Italy for several years. The aim of this multi-center study is to assess the real world persistence on therapy of baricitinib in RA patients and to identify predictive factors of baricitinib's survival rate.

Methods: This is a retrospective, multicentric, Italian, longitudinal study. All patients were enrolled according to the following criteria: a) age ≥ 18 years old; b) diagnosed with RA according 2010 ACR/EULAR classification criteria; c) treated with baricitinib. In order to describe baricitinib clinical efficacy, the survival rate was evaluated by The Kaplan-Meier curve. Then, predictive factors of drug retention rate were assessed by performing the Cox analysis, identifying which risk factors influenced treatment persistence.

Results: Overall, we included 478 patients treated with baricitinib. Among them, 380 (79.5%) were females. Baricitinib's survival rate was 94.6% at 6 months, 87.9% at 12 months, 81.7% at 24 months and 53.4% at 48 months. The Cox analysis regression showed that a higher bDMARDs/tsDMARD line of therapy seems to be a negative prognostic factor for the drug retention rate (HR 1.26 CI 95% 1.07-1.49, p = 0.006.

Conclusion: Real-life study confirms baricitinib effectiveness up to 4 years, but previous treatment with bDMARDs was a negative prognostic factor for its survival rate.

Keywords: Baricitinib; Comorbidity; JAK inhibitors; Line of treatment; Prognostic factor; Real world; Rheumatoid arthritis; Survival rate; bDMARD; tsDMARD.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
4-year survival rate of Baricitinib.
See this image and copyright information in PMC

References

    1. Aletaha D., Neogi T., Silman A.J., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi: 10.1002/art.27584. 2010 Sep. PMID: 20872595. - DOI - PubMed
    1. Baldi C., Berlengiero V., Falsetti P., et al. Baricitinib retention rate: 'real-life' data from a mono-centric cohort of patients affected by rheumatoid arthritis. Front. Med. 2023;10 doi: 10.3389/fmed.2023.1176613. PMID: 37448804; PMCID: PMC10336222. - DOI - PMC - PubMed
    1. Bilgin E., Ceylan F., Duran E., et al. Efficacy, retention and safety of tofacitinib in real-life: hur-bio monocentric experience. Turk. J. Med. Sci. 2020;51(1):297–308. doi: 10.3906/sag-2007-123. - DOI - PMC - PubMed
    1. Chalan P., van den Berg A., Kroesen B.J., Brouwer L., Boots A. Rheumatoid arthritis, immunosenescence and the hallmarks of aging. Curr. Aging Sci. 2015;8(2):131–146. doi: 10.2174/1874609808666150727110744. PMID: 26212057; PMCID: PMC5388800. - DOI - PMC - PubMed
    1. Choy E.H., Miceli-Richard C., Gonzalez-Gay M.A., et al. The effect of jak1/jak2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clin. Exp. Rheumatol. 2019;7:694–704. - PubMed